Citations

Clear

4847 citation(s) found for "Yu, Eric".

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.
Twohy, Erin , Gerstner, Elizabeth R. , Iafrate, A. John , Jeyapalan, Suriya, Lassman, Andrew B. , Schiff, David , Taylor, Jennie , Chowdhary, Sajeel, Morrison, Tara, Kumthekar, Priya , Geyer, Susan M. , Barker, Frederick G., Investigators, Alliance A071401, Brastianos, Priscilla K. , Kaufmann, Timothy J. , Piccioni, David Eric , Fadul, Camilo E. , Kaley, Thomas , Cahill, Daniel P. , Santagata, Sandro , Galanis, Evanthia , Investigators, Alliance A071401

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 2502-2502

10.1200/jco.2020.38.15_suppl.2502 Get It

2502 Background: Patients with progressive or recurrent meningiomas have limited treatment options. Clinical trials of systemic therapies for meningiomas have failed to demonstrate benefit. FAK inhibition has a synthetic lethal relationship with NF2 loss. Given the predominance of NF2 mutations in meningiomas, we evaluated the efficacy of GSK2256098, a FAK inhibitor, as part of the first genomically-driven phase II study in recurrent or progressive grade I-III meningiomas. Methods: Eligible patients (pts) whose tumors screened positively for NF2 mutations were treated with GSK2256098 750mg po bid until progressive disease in 2 separate cohorts: grade I or II/III meningiomas. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate (RR) by Macdonald criteria; per study design, the trial would be declared positive if either endpoint was met. RR was evaluated across the overall cohort; PFS6 was evaluated within each subgroup. Historical benchmark data was obtained from Kaley et al. Neuro Oncol 2014. In the grade I group, 12 evaluable pts provided >79% power to detect a PFS6 rate >65% (vs. null hypothesis of 25%; alpha=0.014). In the grade II/III group, 24 evaluable pts provided >85% power to detect a PFS6 >41.5% (vs. null 15%; alpha=0.02). The threshold for promising results for PFS6 was: 7+/12(grade I) and 8+/24(grade II/III) pts. For RR, 36 evaluable pts provided >94% power to detect RR >20% (vs. null 2.5%; alpha= 0.012). Results: Of 322 pts screened for all mutation cohorts of the study, 36 eligible and evaluable pts with NF2 mutations were enrolled. Across all grades, one pt had a partial response and 24 had stable disease as best response to treatment. In Grade I pts, the observed PFS6 rate was 83% (10/12 pts; 95% CI: 52-98%). In Grade II/III pts, the observed PFS6 rate was 33% (8/24 pts; 95% CI: 16-55%). The study met PFS6 efficacy endpoint both for the Grade I and the Grade II/III cohorts. Treatment was well tolerated. Only 7 patients had a maximum grade-3 adverse event that was at least possibly related to treatment; toxicities across these pts included: proteinuria (2), rash (1), pain (1), ALT (1), AST (1), cholecystitis (1), hypertriglyceridemia (1), apraxia (1), and lymphopenia (1) with no grade 4 or 5 events. Conclusions: GSK2256098 had excellent tolerability andresulted in an improved PFS6 rate in pts with recurrent or progressive NF2-mutated meningiomas. Trial endpoint was met. FAK inhibition warrants further evaluation in this patient population. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org Clinical trial information: NCT02523014 .
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.
Sella, Tal , Gelber, Shari , Poorvu, Philip D. , Kim, Hee Jeong , Arocho, Yaileen D Guzman, Collins, Laura C. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Russell, Christy , Rosenberg, Shoshana M. , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Snow, Craig , Jakubowski, Debbie , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 514-514

10.1200/jco.2020.38.15_suppl.514 Get It

514 Background: The 21- gene Breast Recurrence Score predicts benefit from adjuvant chemotherapy in estrogen receptor positive (ER+), HER-2 negative (-) breast cancer (BC). We aimed to examine whether the 21-gene assay predicts response to neoadjuvant chemotherapy (NAC). Methods: We identified patients with stage I-III ER+/HER2− BC treated with NAC from the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with BC at age ≤ 40 years. The 21-gene assay was performed on tumor specimens removed prior to NAC either as part of clinical care or retrospectively for research. Pathologic complete response (pCR) was defined as no residual invasive tumor (ypT0/is ypN0). The relationship between Recurrence Score result (RS) and pCR was evaluated using logistic regression modeling. Results: 76 women in the cohort had undergone NAC for ER+, HER2- BC and were eligible for this analysis: 5 had undergone clinical 21-gene assay testing, 71 had banked specimens retrospectively tested. Median age at diagnosis was 36.7 (24.3-40). Most tumors were of ductal histology (78%), high grade (51%), progesterone receptor (PgR) positive (86%), ≥T2 (88%), clinically node positive (74%), and anthracycline and taxane containing protocols were administered in 86% of cases. RS ranged between 5-75 with 50% > 25 and only 4 < 11. Mean RS was significantly higher among tumors achieving pCR vs. non-pCR response (51.9 vs. 26.6, pwilcoxon= 0.0005). pCR rate in patients with RS > 25 was 21% (8/38) vs. 5% in patients with RS < 25 (2/38), with both pCRs in the <25 group in patients with RS 21-25. In univariable analysis, PgR negativity (odds ratio (OR) 5.62, 95% confidence interval (CI) 1.27-24.89, p = 0.02), high grade (OR 9.03, 95%CI 1.07-76.32, p = 0.04) and higher RS as a continuous variable (OR 1.08, 95%CI 1.04-1.13, p = 0.0003) were associated with a greater likelihood of pCR. In multivariable analysis only RS remained significantly associated with pCR (OR: 1.07, 95%CI 1.01-1.12, p = 0.01): a 7% increase in the odds of pCR for every 1-point increase in RS. Conclusions: In young women with ER+, HER2- BC who received NAC, higher pretreatment RS was associated with an increased likelihood of pCR. Genomic expression profiling assays may have a role in decision-making in young women in need of neoadjuvant therapy. For women with low likelihood of benefiting from NAC, alternative approaches are clearly warranted. Given the demonstrated efficacy of neoadjuvant endocrine therapy in post-menopausal women, further evaluation in young women should be pursued.
High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display
O’Donovan, Brian D. , Mandel‐Brehm, Caleigh , Liu, Jamin , Parent, Audrey V. , Anderson, Mark S. , Kassimatis, Travis, Ζεκερίδου, Αναστασία , Hauser, Stephen L. , Pittock, Sean J. , Chow, Eric D. , Wilson, Michael R. , Pittock, S J , Chow, Eric , Wilson, Michael R , Vazquez, Sara E. , DeRisi, Joseph L

Mayo Clinic

Brain Communications | May 25, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa059 | PMID 32954318 Get It

Abstract Paraneoplastic neurological disorders are immune-mediated diseases understood to manifest as part of a misdirected anti-tumor immune response. Paraneoplastic neurological disorder-associated autoantibodies can assist with diagnosis and enhance our understanding of tumor-associated immune processes. We designed a comprehensive library of 49-amino-acid overlapping peptides spanning the entire human proteome, including all splicing isoforms and computationally predicted coding regions. Using this library, we optimized a phage immunoprecipitation and sequencing protocol with multiple rounds of enrichment to create high-resolution epitope profiles in serum and cerebrospinal fluid (CSF) samples from patients suffering from two common paraneoplastic neurological disorders, the anti-Yo (n = 36 patients) and anti-Hu (n = 44 patients) syndromes. All (100%) anti-Yo patient samples yielded enrichment of peptides from the canonical anti-Yo (CDR2 and CDR2L) antigens, while 38% of anti-Hu patients enriched peptides deriving from the nELAVL (neuronal embryonic lethal abnormal vision like) family of proteins, the anti-Hu autoantigenic target. Among the anti-Hu patient samples that were positive for nELAVL, we noted a restricted region of immunoreactivity. To achieve single amino acid resolution, we designed a novel deep mutational scanning phage library encoding all possible single-point mutants targeting the reactive nELAVL region. This analysis revealed a distinct preference for the degenerate motif, RLDxLL, shared by ELAVL2, 3 and 4. Lastly, phage immunoprecipitation sequencing identified several known autoantigens in these same patient samples, including peptides deriving from the cancer-associated antigens ZIC and SOX families of transcription factors. Overall, this optimized phage immunoprecipitation sequencing library and protocol yielded the high-resolution epitope mapping of the autoantigens targeted in anti-Yo and anti-Hu encephalitis patients to date. The results presented here further demonstrate the utility and high-resolution capability of phage immunoprecipitation sequencing for both basic science and clinical applications and for better understanding the antigenic targets and triggers of paraneoplastic neurological disorders.
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Cynthia, X. , Leitch, A. Marilyn , Sanati, Souzan , Unzeitig, Gary, Hahn, Olwen, Guenther, J. Michael, Caudle, Abigail S. , Dockter, Travis , Korde, Larissa A. , Weiss, Anna , Hudis, Clifford A. , Alliance, Suman, Vera J. , Vij, Kiran R , Hoog, Jeremy , Watson, Mark A. , Hunt, Kelly K. , Winer, Eric P. , Partridge, Ann H. , Carey, Lisa A. , Ellis, Matthew J. , Alliance

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 504-504

10.1200/jco.2020.38.15_suppl.504 Get It

504 Background: For PM patients (pts) with locally advanced ER+ HER2- BC, NET improves breast conservation surgery (BCS) rates, and modified preoperative endocrine prognostic index (mPEPI) 0, defined as pT1-2 pN0 Ki67< 2.7%, or pathologic complete response (pCR: no invasive disease in breast or lymph node) is associated with low risk of recurrence without adjuvant chemotherapy (CT). The ALTERNATE trial was initiated to assess if the endocrine-sensitive disease rate (ESDR: number of mPEPI 0 pts/number of eligible pts initiating NET) with fulvestrant (F) or F+anastrozole (A) is improved relative to A alone (reported here) and if the 5-year (yr) recurrence-free survival (RFS) rate for pts with mPEPI 0 on A alone without CT is ≥ 95% (awaits further follow-up). Methods: PM pts with clinical stage II/III ER+ HER2- BC were randomized 1:1:1 to 1 mg A po daily, 500 mg F IM every 4 week (wk)s after loading dose, or A+F for 6 months. Ki67 was tested centrally on biopsies acquired prior to NET, wk 4, wk 12 and at surgery. Pts with Ki67 >10% at wk 4 or 12 were recommended to go off protocol-directed ET and switch to CT. Pts with mPEPI 0 at surgery were recommended to continue assigned ET for 1.5 yrs followed by A for a total of 5 yrs ET (and not to receive CT). The primary endpoint of the neoadjuvant phase was ESDR. ESDR of each F arm was compared to that of the A alone arm. With 425 pts per arm, a one-tailed alpha = 0.025 chi-square test of two independent proportions has 84% power to detect an increase of ≥10% in ESDR for F or F+A compared to the A arm, assuming ESDR ≤30% in A. Results: 1362 pts (A 452; F 454; A+F 456) were enrolled Feb 2014 to Nov 2018. 63 pts were excluded (did not start NET). Of the remaining 1299 pts (A 434; F 431, A+F 434), 42% were cN1-3 and 73% were considered candidates for BCS. ESDR was 18.6% (95%CI: 15.1-22.7%) with A, 22.7% (95%CI: 18.9-27.0%) with F, and 20.5% (95%CI: 16.8-24.6%) with A+F. No significant difference in ESDR was found between A and F (p=0.15) or A and A+F (p=0.55). Among the 825 pts with wk 4 Ki67 < 10% who completed NET and surgery, ESDR and the BCS rate were 27.7% and 70.3% with A; 29.6% and 68.1% with F, and 26.8% and 69.9% with A+F, respectively. Conclusion: Neither F nor F+A significantly improved ESDR compared to A alone in PM pts with locally advanced ER+ HER2- BC. RFS data are awaited. Support: U10CA180821, U10CA180882, U24CA196171, https://acknowledgments.alliancefound.org ; NCI BIQSFP, BCRF, Genentech, AstraZeneca. Clinical trial information: NCT01953588 .
Disparities in Objective Sleep Quality as Assessed Through Wrist Actigraphy in Minority Patients With Inflammatory Bowel Disease
Qazi, Taha , Alexander, Megan , Wu, Ting , Noronha, Ansu, Jones, Eric A., Smith, Alexander , Hammer, David A. , Auerbach, Sanford H. , Wasan, Sharmeel K. , Weinberg, Janice , Farraye, Francis A.

Mayo Clinic

Inflammatory Bowel Diseases | May 25, 2020 | Volume: 27 | Issue: 3 | Pages: 371-378

10.1093/ibd/izaa106 | PMID 32448906 Get It

Abstract Background Inflammatory bowel disease (IBD) is associated with a reduced quality of life. Minority patients with IBD specifically report more impairing symptoms compared with nonminority patients. Sleep quality, a key component of quality of life, is significantly compromised in minority patients compared with nonminority patients. Nevertheless, subjective and objective sleep assessments in minority patients with IBD have not explicitly been assessed. The purpose of this prospective cohort study is to assess and compare objective sleep parameters utilizing wrist actigraphy between minority and nonminority IBD patients. Methods In this institutional review board approved study, 74 patients with IBD were recruited and stratified into 2 cohorts by self-identification: white nonminority patients and minority patients. Patients in the minority cohort included black and Hispanic individuals (black and nonblack). Exclusion criteria included significant comorbidity, a history of an underlying sleep disorder, or patients who did not self-identify into categorized cohorts. Sleep was measured not only through wrist-based actigraphy but also with sleep surveys. Sleep parameters were compared between minority and nonminority cohorts. Regression analyses were performed to assess for factors independently associated with parameters of poor sleep quality. Results Sixty-four patients (86.4%) were included in the final analysis. Thirty-one individuals (48.4%) were categorized into the nonminority cohort, and 33 (51.6%) patients were in the minority cohort. A significantly higher number of minority patients had poorer sleep efficiency and fragmented sleep compared with nonminority patients (90.9% vs 67.7%; P = 0.03 and 87.8% vs 61.3%; P = 0.02). In the adjusted analysis, minority status was independently associated with poor sleep efficiency (odds ratio = 6.41; 95% confidence interval, 1.48-28.17; P = 0.0139) and fragmented sleep (odds ratio = 4.98; 95% confidence interval, 1.09-22.89; P = 0.0389). Conclusions Minority patients with IBD were shown to have poorer objective measures of sleep as assessed through wrist actigraphy compared to nonminority patients. Cultural competency in the care of minority patients with IBD, specifically focusing on the management of psychosocial issues, is needed to address these disparities in sleep. The inclusion of minority patients with IBD in studies investigating sleep and other psychosocial issues are warranted not only to assess potential disparities in disease course but also to determine the etiologies of poor sleep in minority patients with IBD.
Mutation prevalence tables for hereditary cancer derived from multigene panel testing
Hart, Steven N. , Yussuf, Amal , Yadav, Siddhartha , Goldgar, David E. , Hu, Chunling , LaDuca, Holly , Smith, Laura P., Fujimoto, June, Li, Shuwei , Dolinsky, Jill S. , Polley, Eric C. , Yadav, Siddhartha , Hart, Steven N , Hu, Chunling , Couch, Fergus J.

Mayo Clinic

Human Mutation | May 22, 2020 | Volume: 41 | Issue: 8 | Pages: No page available

10.1002/humu.24053 | PMID 32442341 Get It

Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Zhou, Yalu, Han, Cuijuan , Wang, Eric , Lorch, Adam H., Serafin, Valentina , Cho, Byoung-Kyu , Gutierrez-Diaz, Blanca T. , Calvo, Julien , Fang, Celestia, Khodadadi‐Jamayran, Alireza , Tabaglio, Tommaso , Marier, Christian, Kuchmiy, Anna , Sun, Limin , Yacu, George, Filip, Szymon K. , Jin, Qi , Takahashi, Yoh-hei, Amici, David R. , Rendleman, Emily J. , Rawat, Radhika , Paganin, Maddalena , Kandela, Irawati , Politanska, Yuliya , Palhais, Bruno , Vlierberghe, Pieter Van , Taghon, Tom , Aifantis, Iannis , Goo, Young Ah , Guccione, Ernesto , Heguy, Adriana , Tsirigos, Aristotelis , Wee, Keng Boon , Mishra, Rama K. , Pflumio, Françoise , Accordi, Benedetta , Ntziachristos, Panagiotis , Jin, Qi , Taghon, Tom , Goo, Young Ah , Tsirigos, Aristotelis , Basso, Giuseppe , Khodadadi-Jamayran, Alireza , Van Vlierberghe, Pieter , Gutierrez Diaz, Blanca , Cho, Byoung-Kyu , Han, Cuijuan , Serafin, Valentina , Jin, Qi , Takahashi, Yoh-Hei, Bresolin, Silvia , Zhang, Cheng , Li, Hu , Abdala‐Valencia, Hiam , Mendillo, Marc L. , Zhu, Ping, Basso, Giuseppe , Jin, Qi

Mayo Clinic

Cancer Discovery | May 22, 2020 | Volume: 10 | Issue: 9 | Pages: 1388-1409

10.1158/2159-8290.cd-19-1436 | PMID 32444465 Get It

Abstract Splicing alterations are common in diseases such as cancer, where mutations in splicing factor genes are frequently responsible for aberrant splicing. Here we present an alternative mechanism for splicing regulation in T-cell acute lymphoblastic leukemia (T-ALL) that involves posttranslational stabilization of the splicing machinery via deubiquitination. We demonstrate there are extensive exon skipping changes in disease, affecting proteasomal subunits, cell-cycle regulators, and the RNA machinery. We present that the serine/arginine-rich splicing factors (SRSF), controlling exon skipping, are critical for leukemia cell survival. The ubiquitin-specific peptidase 7 (USP7) regulates SRSF6 protein levels via active deubiquitination, and USP7 inhibition alters the exon skipping pattern and blocks T-ALL growth. The splicing inhibitor H3B-8800 affects splicing of proteasomal transcripts and proteasome activity and acts synergistically with proteasome inhibitors in inhibiting T-ALL growth. Our study provides the proof-of-principle for regulation of splicing factors via deubiquitination and suggests new therapeutic modalities in T-ALL. Significance: Our study provides a new proof-of-principle for posttranslational regulation of splicing factors independently of mutations in aggressive T-cell leukemia. It further suggests a new drug combination of splicing and proteasomal inhibitors, a concept that might apply to other diseases with or without mutations affecting the splicing machinery. This article is highlighted in the In This Issue feature, p. 1241
Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk
Zhu, Jingjing , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L. , Du, Mengmeng , Goodman, Phyllis J. , Li, Donghui , Bracci, Paige M. , Gallinger, Steven , Arslan, Alan A. , Scélo, Ghislaine , Visvanathan, Kala , Haiman, Christopher A. , Petersen, Gloria M. , Wu, Lang , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L , Malats, Nuria , Duell, Eric J , Li, Donghui , Katzke, Verena , Van Den Eeden, Stephen K , Arslan, Alan A , Canzian, Federico , Yu, Herbert , Klein, Alison P , Visvanathan, Kala , Guo, Xingyi , Liu, Duo, Giles, Graham G. , Wu, Chong , White, Emily , Risch, Harvey A. , Malats, Núria , Duell, Eric J. , Neale, Rachel Ε. , Canzian, Federico , Kooperberg, Charles , Freeman, Laura E. Beane , Marchand, Loı̈c Le , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Cai, Qiuyin , Long, Jirong , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 21, 2020 | Volume: 29 | Issue: 7 | Pages: 1501-1508

10.1158/1055-9965.epi-20-0091 | PMID 32439797 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with few known risk factors and biomarkers. Several blood protein biomarkers have been linked to PDAC in previous studies, but these studies have assessed only a limited number of biomarkers, usually in small samples. In this study, we evaluated associations of circulating protein levels and PDAC risk using genetic instruments. Methods: To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium, using genetic instruments of protein quantitative trait loci. Results: We observed associations between predicted concentrations of 38 proteins and PDAC risk at an FDR of &lt; 0.05, including 23 of those proteins that showed an association even after Bonferroni correction. These include the protein encoded by ABO, which has been implicated as a potential target gene of PDAC risk variant. Eight of the identified proteins (LMA2L, TM11D, IP-10, ADH1B, STOM, TENC1, DOCK9, and CRBB2) were associated with PDAC risk after adjusting for previously reported PDAC risk variants (OR ranged from 0.79 to 1.52). Pathway enrichment analysis showed that the encoding genes for implicated proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL15 production. Conclusions: We identified 38 candidates of protein biomarkers for PDAC risk. Impact: This study identifies novel protein biomarker candidates for PDAC, which if validated by additional studies, may contribute to the etiologic understanding of PDAC development.
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications
Oren, Ohad , Yang, Eric H. , Gluckman, Ty J. , Michos, Erin D. , Blumenthal, Roger S. , Gersh, Bernard J. , Gersh, Bernard J , Yang, Eric , Michos, Erin D

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 21, 2020 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/circep.120.008688 | PMID 32436730 Get It

Management of Cancer Cachexia: ASCO Guideline
Roeland, Eric , Bohlke, Kari , Fabbro, Egidio Del , Dixon, Suzanne , Fallon, Marie , Herrstedt, Jørn , Lau, Harold , Schnipper, Hester Hill, Tan, Winston , Loprinzi, Charles L. , Roeland, Eric J , Baracos, Vickie E. , Bruera, Eduardo , Platek, Mary, Rugo, Hope S. , Smith, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | May 20, 2020 | Volume: 38 | Issue: 21 | Pages: 2438-2453

10.1200/jco.20.00611 | PMID 32432946 Get It

PURPOSE To provide evidence-based guidance on the clinical management of cancer cachexia in adult patients with advanced cancer. METHODS A systematic review of the literature collected evidence regarding nutritional, pharmacologic, and other interventions, such as exercise, for cancer cachexia. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and systematic reviews of RCTs published from 1966 through October 17, 2019. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS The review included 20 systematic reviews and 13 additional RCTs. Dietary counseling, with or without oral nutritional supplements, was reported to increase body weight in some trials, but evidence remains limited. Pharmacologic interventions associated with improvements in appetite and/or body weight include progesterone analogs and corticosteroids. The other evaluated interventions either had no benefit or insufficient evidence of benefit to draw conclusions on efficacy. Limitations of the evidence include high drop-out rates, consistent with advanced cancer, as well as variability across studies in outcomes of interest and methods for outcome assessment. RECOMMENDATIONS Dietary counseling may be offered with the goals of providing patients and caregivers with advice for the management of cachexia. Enteral feeding tubes and parenteral nutrition should not be used routinely. In the absence of more robust evidence, no specific pharmacological intervention can be recommended as the standard of care; therefore, clinicians may choose not to prescribe medications specifically for the treatment of cancer cachexia. Nonetheless, when it is decided to trial a drug to improve appetite and/or improve weight gain, currently available pharmacologic interventions that may be used include progesterone analogs and short-term (weeks) corticosteroids.